• Tevogen Bio Holdings entered a signed, non-exclusive, non-binding letter of intent to evaluate a potential acquisition of a management services organization.
• The deal is positioned to expand Tevogen’s healthcare infrastructure and support a broader push into healthcare services alongside its biotech and AI units.
• Management said the MSO evaluation, combined with a previously disclosed review of a contract research organization and other acquisition efforts, could support a path toward about $100 million in combined annual revenue if completed.
• The potential transaction remains subject to due diligence, definitive documentation, required approvals, and customary closing conditions.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Tevogen Bio Holdings Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202605211215PRIMZONEFULLFEED9724837) on May 21, 2026, and is solely responsible for the information contained therein.